Navigation Links
ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
Date:2/25/2008

- $2 M to ProMetic over the next 12 months

- $30 M plus potential annual revenue to ProMetic derived from first

hyperimmune product

- Kedrion has in-licensed ProMetic's yield improving technology - Incorporation of ProMetic's prion reduction technology in Kedrion's

manufacturing process

MONTREAL, Feb. 26 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. ("ProMetic") (TSX:PLI) announced today that it has signed the definitive agreement for development of two hyperimmunes with Kedrion S.p.A. ("Kedrion").

Terms of this agreement call for upfront and milestone payments, as well as service fees to ProMetic amounting to $2 M over the next 12 months.

Potential revenues to ProMetic from Hepatitis B Hyperimmune are to exceed $30 M annually, and are derived from royalties on Kedrion sales in Europe and ProMetic sales in North America, which are expected to commence in 2011.

The first product to be developed will target the Hepatitis B Hyperimmune market which is currently estimated in Europe and in the U.S. to be at $200 M and is expected to be at $400 M by 2015.

Kedrion has in-licensed ProMetic's technologies for the manufacturing of hyperimmune products in Europe. Royalties, licensing and service fees for the sales of products in Europe will be paid by Kedrion to ProMetic with ProMetic retaining the commercial rights for the fully developed hyperimmune products for the North American market. ProMetic will in turn pay Kedrion royalties on its sales of the hyperimmune products in North America.

The product development program, including the clinical trial designed to meet U.S. and European regulatory requirements will be funded by Kedrion. Full scale commercial manufacturing will then take place in Kedrion's facility in Italy.

"This agreement with Kedrion will leverage ProMetic's ability to penetrate into the North American hyperi
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
2. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
3. ProMetic provides business update - Over $35 million worth of business secured in January
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014  Spherix Incorporated (SPEX) -- an intellectual property development ... property, today announced that the United States Patent & ... in the month of August that are part of ... The issued patents are: , U.S.RE45,065 ... 19, 2014; and , U.S.RE45,095 issued August 26, ...
(Date:9/1/2014)... Sept. 1, 2014 Reportlinker.com announces that ... its catalogue: India Solid Waste Management ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html In ... main governing bodies responsible for complete handling and ... an average, around 135,000 MT solid waste is ...
(Date:8/31/2014)... PARSIPPANY, N.J. , Aug. 31, 2014 ... New Drug Discovery program in Anti-Infective research when two ... the coveted Qualified Infectious Disease Product (QIDP) status from ... granted to drugs which act against pathogens which have ... and are identified by Centre for Disease Control (a ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 This ... current state of the Epoxy Hardener industry ... basic overview of the industry, including definitions, applications ... Chinese domestic market analysis are provided with a ... of the market. A comparison between the international ...
Breaking Biology Technology:United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3
... Medarex, Inc. (Nasdaq: MEDX ) is ... at 8:30 a.m. Eastern Time on Thursday, April 30, ... for the first quarter of 2009.To access the call ... webcast can be accessed through the Investor Relations section ...
... Integrity Provider First to Bring IP Ownership into Discussion , ... ... LLC , the leading provider of data integrity solutions, announced today ... and only data integrity protection provider of its kind ...
... BioMS Medical Corp (TSX: MS), a leading developer in the ... Giese, President and CEO, will present at a session entitled ... technology sector" as part of the Alberta Economic Forum in ... Monday May 4th at 10:05am (Local time), ...
Cached Biology Technology:Medarex to Host Business and Financial Update Conference Call on Thursday, April 30, 2009 2Surety, LLC Joins Microsoft BioIT Alliance 2Surety, LLC Joins Microsoft BioIT Alliance 3BioMS Medical to present at Alberta Economic Forum in Geneva 2
(Date:9/2/2014)... Society of Human Genetics (ASHG) and the National ... National Institutes of Health, have named Elizabeth P. ... Wellington School in Columbus, Ohio, the first ASHG/NHGRI ... today. , The Genetics and Education Fellowship is ... skills, experience, and network to prepare for a ...
(Date:9/2/2014)... COLLEGE PARK, Md. -- A team of University ... that they and other scientists say make possible ... ranging from clean energy and quantum computing advances ... September 2, issue of Nature Communications ... new synthesis strategy for hybrid nanostructures that uses ...
(Date:9/2/2014)... FL, September 2, 2014 In a new study ... from the Florida campus of The Scripps Research Institute ... cells into unique manufacturing sites for molecules that can ... a cell as a reaction vessel and a disease-causing ... a diseased cell," said TSRI Professor Matthew Disney.,"Because the ...
Breaking Biology News(10 mins):ASHG and NHGRI award first genetics and education fellowship 2New synthesis method may shape future of nanostructures, clean energy 2New synthesis method may shape future of nanostructures, clean energy 3Scripps Florida scientists make diseased cells synthesize their own drug 2
... of Alzheimer,s disease reports improvement in language abilities ... the research, published today in the open access ... minutes of using this new treatment. Building ... in BioMed Central,s Journal of Neuroinflammation, ...
... to be the niche. As air and water preceded life, ... cells in many tissues and provides factors necessary to keep ... cell dependents. A team of scientists at the ... assistant professor in the Laboratory of Genetics, now suggests that ...
... the burgeoning field of interventional therapies for congenital ... Vegas July 20-23 for the Pediatric & Adult ... Medical Center in Chicago will perform live cases ... On Monday, July 21st, Dr. Ziyad M. ...
Cached Biology News:Stem cell chicken and egg debate moves to unlikely arena: the testes 2Stem cell chicken and egg debate moves to unlikely arena: the testes 3Latest advances in interventional cardiology for congenital heart disease presented 2
MAb to Transferrin Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Rabbit polyclonal to IRS1 (phospho S636) ( Abpromise for all tested applications). entrezGeneID: 3667 SwissProtID: P35568...
Leucine-rich repeat-containing G-protein coupled receptor 4...
Rabbit polyclonal to MDM2 (phospho S185) ( Abpromise for all tested applications). entrezGeneID: 4193 SwissProtID: Q00987...
Biology Products: